Efficacious treatment of experimental leishmaniasis with amphotericin B- arabinogalactan water-soluble derivatives

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2209-2214

  Golenser, Jacob ^a   Frankenburg, Shoshana ^b   Ehrenfreund, Tirtsa ^c   Domb, Abraham J ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ARABINOGALACTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032826465     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2209     Document Type: Article

References (21)

1. Adams, M. F., and C. Douglas. 1963. Arabinogalactan - a review of the literature. TAPPI 46:544-558.
2. Al-Abdely, H. M., J. R. Graybill, R. Bocanegra, L. Najvar, E. Montalbo, S. L. Regen, and P. C. Melby. 1998. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental marine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob. Agents Chemother. 42: 2542-2548.
3. Allen, S., and R. A. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711. In D. T. Hart (ed.), Leishmaniasis. Plenum Publishing Corporation, London, United Kingdom.
4. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
5. Chabot, G. G., R. Pazdur, F. A. Valeriote, and L. H. Baker. 1989. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78:307-310.
6. Cohen, R., I. Polacheck, S. Benita, M. Levi, and Y. Barenholz. 1996. Comparative evaluation of five types of amphiphile-based assemblies containing amphotericin B. In Program and Abstracts of the Conference on Liposome Advances: Progress in Drug Delivery and Vaccine Delivery. Centre for Drug Delivery Research, School of Pharmacy, University of London, London, United Kingdom.
7. Coukell, A. J., and R. N. Brogden. 1998. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585-612.
8. di Martino, L., R. N. Davidson, R. Giacchino, S. Scotti, F. Raimondi, E. Casstagnola, L. Tasso, A. Cascio, L. Gradoni, M. Gramiccia, M. Pettoellomantovani, and A. D. M. Bryceson. 1997. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J. Pediatr. 131:271-277.
9. Durand, R., M. Paul, F. Pratlong, D. Rivollet, M. L. Dubreuil-Lemaire, R. Houin, A. Astier, and M. Deniau. 1998. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob. Agents Chemother. 42:2141-2143.
10. Falk, R., A. J. Domb, and I. Polacheck. 1999. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43:1975-1981.
11. Gangneux, J. P., A. Sulahian, Y. J. F. Garin, and F. Derouin. 1996. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans. R. Soc. Trop. Med. Hyg. 90:574-577.
12. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 2:S133-S144.
13. Legrand, P., M. Cheron, L. Leroy, and J. Bolard. 1997. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Target. 4:311-319.
14. Maddux, M. S., and S. L. Barriere. 1980. A review of complications of amphotericin B therapy: recommendation for prevention and management. Drug Intell. Clin. Pharm. 14:177-181.
15. Maeda, H. 1994. Polymer-conjugated macromolecular drugs for tumor-specific targetting, p. 95-116. In A. Domb (ed.), Polymeric site-specific pharmacotherapy. John Wiley and Sons, Chichester, United Kingdom.
16. Mishra, M., U. K. Biswas, A. M. Jha, and A. B. Khan. 1994. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 344:1599-1600.
17. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
18. Nazareth, M. R., V. L. Narayanan, and V. A. Bhatia. 1961. Studies on the larch arabogalactan II. J. Pharm. Sci. 50:564-567.
19. Paul, M., R. Durand, H. Fessi, D. Rivollet, R. Houin, A. Astier, and M. Deniau. 1997. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41:1731-1734.
20. Thakur, C. P., S. Narain, N. Kumar, S. M. Hassan, D. K. Jha, and A. Kumar. 1997. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post kala azar dermal leishmaniasis. Ann. Trop. Med. Parasitol. 91:611-616.
21. Yardley, V., and S. Croft. 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41: 752-756.